A Study of Baricitinib (LY3009104) in Participants With Moderate to Severe Atopic Dermatitis

Clinical trial NCT03559270 · TERMINATED

Trial details

NCT number: NCT03559270
Sponsor: Eli Lilly and Company
Status: TERMINATED
Phase: Phase 3
Study type: INTERVENTIONAL

Atopic Dermatitis

Start date: 2018-06-27
Primary completion: 2021-10-14
Enrollment: 374

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.